KRTX 外国為替ニュース

Bristol-Myers Squibb Co. (BMY) and biopharmaceutical company Karuna Therapeutics, Inc. (KRTX) announced Friday that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.